Boston Scientific reported a solid Q2 2026 with 7% organic growth, but significantly lowered its full-year and Q3 guidance due to a sharp slowdown in EP and Watchman markets. The company is facing competitive pressures in the US EP market and a surprising decline in Watchman procedures, leading to a pivot to focus on cost restructuring and long-term growth in new markets. Q2 2026 organic revenue grew 7%, reaching $5.442B, in line with prior guidance, but EPS of $0.86 beat expectations.
Buzzberg readGuidance cut driven by EP and Watchman slowdownsBoston Scientific reported a solid Q2 2026 with 7% organic growth, but significantly lowered its full-year and Q3 guidance due to a sharp slowdown in EP and Watchman markets. The company is facing competitive pressures in the US EP market and a surprising decline in Watchman procedures, leading to a pivot to focus on cost restructuring and long-term growth in new markets. Q2 2026 organic revenue grew 7%, reaching $5.442B, in line with prior guidance, but EPS of $0.86 beat expectations.Read full analysisCollapse analysis
Boston Scientific reported a solid Q2 2026 with 7% organic growth, but significantly lowered its full-year and Q3 guidance due to a sharp slowdown in EP and Watchman markets. The company is facing competitive pressures in the US EP market and a surprising decline in Watchman procedures, leading to a pivot to focus on cost restructuring and long-term growth in new markets. Q2 2026 organic revenue grew 7%, reaching $5.442B, in line with prior guidance, but EPS of $0.86 beat expectations.
Full-year 2026 guidance was cut to 5-6% organic growth and $3.28-$3.32 EPS, reflecting a sharp deterioration in the EP and Watchman markets.
EP growth is under pressure from rapid PFA market adoption and competitive share loss; US EP Q3 sales are expected to fall sequentially.
Watchman market has slowed unexpectedly due to clinical evidence and operational inefficiencies from concomitant procedure adoption, leading to reduced guidance.
Revenue$5.442B
+5% QoQ
EPS$0.86
+7% QoQ
Gross margin70.71%
reported
Op margin21.65%
reported
What changed this quarter
01
Guidance
Guidance cut driven by EP and Watchman slowdowns
Guidance · revenue to 4%
02
Demand
Watchman second half to decline mid-to-high single digits
Management acknowledged significant near-term headwinds in EP and Watchman, lowered guidance, and emphasized a realistic outlook, while expressing confidence in long-term drivers.
03
Demand
EP second half growth expected flat globally
Watchman second half to decline mid-to-high single digits. Management acknowledged significant near-term headwinds in EP and Watchman, lowered guidance, and emphasized a realistic outlook, while expressing confidence in long-term drivers.
04
Margins
Restructuring to deliver $500 million run-rate savings
Reported gross margin was 70.71%, reinforcing the quarter's better-than-guided profitability.
Demand
Demand
Bookings & conversion
Watchman second half to decline mid-to-high single digits. Management acknowledged significant near-term headwinds in EP and Watchman, lowered guidance, and emphasized a realistic outlook, while expressing confidence in long-term drivers.
Tone · Cautious
Management acknowledged significant near-term headwinds in EP and Watchman, lowered guidance, and emphasized a realistic outlook, while expressing confidence in long-term drivers.
Supply-chain alpha
A1
US PFA market has rapidly accelerated to ~80-85% share of AFib ablation, faster than anticipated, and is causing share loss for BSX's Farapulse platform.
“We believe that the US PFA revenue now makes up approximately 80% of the AFib market, which does limit our ability to offset some competitive pressures.”
A significant portion (one-third) of Watchman procedures are now done concomitantly with other cardiac procedures, and this is creating operational inefficiencies and slowing overall LAAC market growth.
“The fast adoption of concomitant procedures has created inefficiencies in the system with regards to operationalize both standalone and concomitant and allowing for sustained growth.”
… that our IC business and ICBT broadly will be our strongest growth driver for Boston Scientific as we enter a number of high growth adjacent markets over the coming years. Our vascular therapies business grew 8% driven by broader adoption of Varathena in our drug looting portfolio. We're pleased with the performance of our seismic IVL launch with strong reception for the clinical differentiation of the device We continue to ramp supply. We remain excited about the opportunity to add the Penumbra team in a highly differentiated and complementary portfolio to Boston Scientific. We anticipate the deal will close in the second half of 26, subject to the receipt of the remaining regulatory clearances. Our interventional oncology and embolization business grew 12% driven by strong global growth with our broad offering of innovative technologies. Earlier this month, results from the PROACTIVE, which is a large prospective real-world study evaluating therosphere and the treatment of liver malignancies were published. The study demonstrated meaningful survival outcomes across all stages of disease, including patients with larger or more advanced tumors, further supporting the use of …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.